What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Josep Tabernero focuses on Internal medicine, Colorectal cancer, Oncology, Cancer and Surgery.
Josep Tabernero regularly links together related areas like Gastroenterology in his Internal medicine studies.
His Colorectal cancer study incorporates themes from Stage and Adjuvant therapy.
His Oncology research is multidisciplinary, incorporating elements of Irinotecan, Pathology, Hazard ratio, Bevacizumab and Panitumumab.
His research integrates issues of Cancer research, Tolerability, Immunology, Intensive care medicine and Pharmacology in his study of Cancer.
As a part of the same scientific study, Josep Tabernero usually deals with the Clinical trial, concentrating on Randomized controlled trial and frequently concerns with Placebo.
His most cited work include:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine (3192 citations)
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer (2651 citations)
- The landscape of somatic copy-number alteration across human cancers (2544 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Colorectal cancer, Cancer and Cancer research.
His research in Internal medicine intersects with topics in Gastroenterology and Surgery.
His Surgery research is multidisciplinary, relying on both Placebo and Hazard ratio.
His Oncology research is multidisciplinary, incorporating perspectives in Bevacizumab, Gemcitabine, Irinotecan and Clinical trial.
His Colorectal cancer study combines topics in areas such as Biomarker and Fluorouracil.
His research in Cancer tackles topics such as Pharmacology which are related to areas like PI3K/AKT/mTOR pathway.
He most often published in these fields:
- Internal medicine (63.47%)
- Oncology (51.63%)
- Colorectal cancer (37.54%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (63.47%)
- Oncology (51.63%)
- Colorectal cancer (37.54%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Colorectal cancer, Cancer and Cancer research.
His Internal medicine research incorporates elements of Gastroenterology and Placebo.
The concepts of his Oncology study are interwoven with issues in Gemcitabine, Irinotecan, FOLFOX and Targeted therapy.
Josep Tabernero focuses mostly in the field of Colorectal cancer, narrowing it down to topics relating to Bevacizumab and, in certain cases, Oxaliplatin.
His work carried out in the field of Cancer brings together such families of science as Disease and MEDLINE.
Josep Tabernero studied Cancer research and CD8 that intersect with T cell, T-cell receptor and Cell.
Between 2018 and 2021, his most popular works were:
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer (277 citations)
- Caring for patients with cancer in the COVID-19 era. (135 citations)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. (130 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Internal medicine, Oncology, Cancer, Clinical trial and Colorectal cancer.
His Internal medicine study frequently intersects with other fields, such as Gastroenterology.
His studies in Oncology integrate themes in fields like Gemcitabine, Survival analysis, Regimen and Cohort.
His Cancer research includes elements of Data sharing, Cancer research, Disease and MEDLINE.
The study incorporates disciplines such as Precision medicine, Tyrosine, Progression-free survival, Transforming growth factor beta and Immunotherapy in addition to Clinical trial.
His research links Binimetinib with Colorectal cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
